October 5, 2021 – T-CURE BIOSCIENCE, INC. AND ATLAS ANTIBODIES AB ENTER A COLLABORATION AGREEMENT FOR THE DEVELOPMENT, MANUFACTURE, AND SUPPLY OF CT83 (KK-LC-1) MONOCLONAL ANTIBODIES
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, [...]
September 15, 2021 – T-CURE BIOSCIENCE ANNOUNCES U.S. FDA CLEARANCE OF INVESTIGATOR – INITIATED CLINICAL TRIAL FOR KK-LC-1 TCR-T AGAINST MULTIPLE SOLID TUMORS
LOS ANGELES, CA, September 15, 2021 T-Cure Bioscience, Inc., [...]
September 10, 2021 – T-CURE BIOSCIENCE ANNOUNCED PRESENTATIONS AT THREE UPCOMING HEALTHCARE CONFERENCES
Sherman Oaks, CA – September 10, 2021 - T-Cure Bioscience, [...]
April 16, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that management will present virtually at the following upcoming webinar and healthcare conference:
Sherman Oaks, CA – April 16, 2021 - T-Cure [...]
March 17, 2021 – T-Cure Bioscience Enters Into Agreement With Rutgers to Conduct Clinical Research of Novel T Cell Receptor Therapy for Treatment of Variety of Cancers
Sherman Oaks, CA – March 17, 2021 - T-Cure [...]
January 20, 2021 – T-Cure Bioscience and Immunotech Biopharm Ltd. Announce License Agreement for Novel HERV-E T Cell Receptor Therapy
Immunotech Biopharm Ltd will have rights to develop and [...]